Success Metrics

Clinical Success Rate
79.1%

Based on 1,063 completed trials

Completion Rate
79%(1063/1344)
Active Trials
587(25%)
Results Posted
67%(707 trials)
Terminated
281(12%)

Phase Distribution

Ph phase_3
476
21%
Ph phase_4
18
1%
Ph phase_1
605
26%
Ph not_applicable
33
1%
Ph phase_2
1,137
49%
Ph early_phase_1
14
1%

Phase Distribution

619

Early Stage

1137

Mid Stage

494

Late Stage

Phase Distribution2283 total trials
Early Phase 1First-in-human
14(0.6%)
Phase 1Safety & dosage
605(26.5%)
Phase 2Efficacy & side effects
1,137(49.8%)
Phase 3Large-scale testing
476(20.8%)
Phase 4Post-market surveillance
18(0.8%)
N/ANon-phased studies
33(1.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

74.4%

1063 of 1428 finished

Non-Completion Rate

25.6%

365 ended early

Currently Active

587

trials recruiting

Total Trials

2,306

all time

Status Distribution
Active(649)
Completed(1063)
Terminated(365)
Other(229)

Detailed Status

Completed1063
Recruiting320
Terminated281
Active, not recruiting267
unknown227
Withdrawn84

Development Timeline

Analytics

Development Status

Total Trials
2306
Active
587
Success Rate
79.1%
Most Advanced
Phase 4

Trials by Phase

Early Phase 114 (0.6%)
Phase 1605 (26.5%)
Phase 21137 (49.8%)
Phase 3476 (20.8%)
Phase 418 (0.8%)
N/A33 (1.4%)

Trials by Status

not_yet_recruiting603%
unknown22710%
active_not_recruiting26712%
suspended20%
enrolling_by_invitation20%
terminated28112%
completed106346%
withdrawn844%
recruiting32014%

Recent Activity

Clinical Trials (2,306)

Showing 20 of 2,306 trialsScroll for more
NCT03606967Phase 2

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

Recruiting
NCT06843447Phase 1

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)

Recruiting
NCT07281417Phase 2

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

Recruiting
NCT05058651Phase 2

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

Recruiting
NCT07646301Phase 2

Iparomlimab and Tuvonralimab Plus Paclitaxel and Platinum as Neoadjuvant Therapy for Locally Advanced Cervical Cancer

Recruiting
NCT06694454Phase 1

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Recruiting
NCT01154920Phase 2

Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

Active Not Recruiting
NCT07227597Phase 1

A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)

Recruiting
NCT06422143Phase 3

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

Recruiting
NCT07005128Phase 3

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

Recruiting
NCT06172296Phase 3

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Recruiting
NCT07216703Phase 3

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

Recruiting
NCT07252739Phase 2

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

Recruiting
NCT04267848Phase 3

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Recruiting
NCT06772623Phase 1

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Recruiting
NCT07486817Phase 2

Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab

Recruiting
NCT06966700Phase 3

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Recruiting
NCT00494182Phase 2

Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer

Active Not Recruiting
NCT07198074Phase 3

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

Recruiting
NCT06841354Phase 3

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
2,306